What is TARA's current stock price?

TARA (Protara Therapeutics, Inc.) is currently trading at $4.92 with a market cap of $189.9M.

What sector is Protara Therapeutics, Inc. in?

Protara Therapeutics, Inc. (TARA) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is TARA a good stock to buy?

Analysts have a Buy consensus on TARA with a price target of $12.00. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

TARA Protara Therapeutics, Inc.

Healthcare

$4.92-1.01%ClosedMarket Cap: $189.9M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

1.16

P/S

0.00

EV/EBITDA

-2.56

DCF Value

$1.03

FCF Yield

-33.2%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-38.7%

ROA

-33.0%

ROIC

-38.0%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$0.00	$-17.8M	$—
Q4 null	$0.00	$-17.3M	$—
FY null	$0.00	$-57.4M	$—
Q3 null	$0.00	$-13.3M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$12.00

Target (Median)

$12.00

Target Range

$12.00 - $12.00

2 Strong Buy6 Buy0 Hold0 Sell0 Strong Sell

OppenheimerOutperform

2026-05-20

JP MorganOverweight

2026-05-14

HC Wainwright & Co.Buy

2026-04-29

HC Wainwright & Co.Buy

2026-02-10

HC Wainwright & Co.Buy

2025-12-03

Trading Activity

Insider Trades

View All

Zummo Jacquelineofficer: Chief R&D Officer

SellThu Apr 09

Zummo Jacquelineofficer: Chief R&D Officer

SellThu Apr 02

Zummo Jacquelineofficer: Chf Scientific Operations Off

SellTue Jan 27

Shefferman Jessedirector, officer: CEO and President

SellTue Jan 27

Fry Hannahofficer: VP, Controller

SellTue Jan 27

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

1.52

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.

Peers